ROBERT T. JENSEN, M.D.; JERRY D. GARDNER, M.D.; JEAN-PIERRE RAUFMAN, M.D.; STEPHEN J. PANDOL, M.D.; JOHN L. DOPPMAN, M.D.; MARTIN J. COLLEN, M.D.
Over the last few years the approach to managing patients with the Zollinger-Ellison syndrome has changed dramatically. The establishment of gastrin hypersecretion by a non-beta islet cell tumor as responsible for the gastric acid hypersecretion, and the subsequent development and widespread availability of gastrin radioimmunoassays have changed the criteria generally used for diagnosis and have led to an increased understanding of syndromes that can mimic Zollinger-Ellison syndrome. With the availability of histamine H2-receptor antagonists, gastric acid hypersecretion can be controlled medically in almost all patients with Zollinger-Ellison syndrome, obviating routine total gastrectomy. With the reduced mortality from gastric acid hypersecretion, increased attention is being focused on the natural history of the gastrinoma. Newer methods of localizing tumors are being investigated with a view to surgical removal of the gastrinoma, and the importance of developing an effective chemotherapeutic regimen is becoming increasingly apparent.
JENSEN RT, GARDNER JD, RAUFMAN J, PANDOL SJ, DOPPMAN JL, COLLEN MJ. Zollinger-Ellison Syndrome: Current Concepts and Management. Ann Intern Med. ;98:59–75. doi: 10.7326/0003-4819-98-1-59
Download citation file:
Published: Ann Intern Med. 1983;98(1):59-75.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use